登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心中国医学科学院血液病医院(血液学研究所)Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC天津医院页面
- 研究中心江苏省人民医院(南医大一附院)Jiangsu Province Hospital南京医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06743503,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Have 2 negative pregnancy tests verified (one negative serum beta human chorionic gonadotropin [β-hCG] at screening and another within 48 hours prior to treatment withUB-VV400).
入选标准第 14 条
Treatment with prior CD22-directed therapy except for UB-VV400.
排除标准第 5 条
Ongoing Grade > 2 toxicities from the last line of anticancer therapy.
排除标准第 9 条
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
入选标准第 6 条
Renal function: serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) or creatinine clearance ≥ 45 mL/min.
入选标准第 9 条
Alanine aminotransferase (ALT) ≤ 2.5 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, AND total bilirubin < 1.5 × ULN.
入选标准第 11 条
Systemic autoimmune diseases or immunodeficiency diseases (except for well-controlled type I diabetes with hemoglobin A1C [HbA1c] less than 8% or well-controlled thyroid disease, as assessed by the treating physician).
排除标准第 14 条
Measurable disease according to Lugano 2014 criteria.
入选标准第 4 条
History of or active human immunodeficiency virus (HIV).
排除标准第 6 条
Commit to "true abstinence" from heterosexual intercourse or agree to use and complywith highly effective, uninterrupted contraception for 12 months after administration of UB-VV400 .
入选标准第 15 条
Abstain from breastfeeding for 12 months following administration of UB-VV400.
入选标准第 16 条
Men with partners of childbearing potential must commit to "true abstinence" from heterosexual intercourse or agree to use a highly effective form of contraception duringheterosexual contact with a pregnant individual or any individual of childbearing potential for 12 months after administration of UB-VV400, regardless of past vasectomy.
入选标准第 17 条
Women who are pregnant or breastfeeding.
排除标准第 1 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06743503,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age ≥ 18 at time of consent. Provide voluntary written informed consent. Relapsed/refractory disease for subjects that are either CAR T-naive or CAR T-exposed. Measurable disease according to Lugano 2014 criteria. No serious concomitant diseases or active/uncontrolled infections. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Cardiac function: left ventricular ejection fraction (LVEF) ≥ 40%. Pulmonary function: pulse oximetry ≥ 90% on room air at rest. Renal function: serum creatinine ≤ 1.5 × age-adjusted upper limit of normal (ULN) or creatinine clearance ≥ 45 mL/min. Absolute lymphocyte count (ALC) ≥ 0.2×10\^9/L. Alanine aminotransferase (ALT) ≤ 2.5 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, AND total bilirubin < 1.5 × ULN. No ongoing coagulopathies requiring periodic replacement of clotting factors (eg, fresh frozen plasma, cryoprecipitate). Women of childbearing potential must: Have 2 negative pregnancy tests verified (one negative serum beta human chorionic gonadotropin [β-hCG] at screening and another within 48 hours prior to treatment withUB-VV400). Commit to "true abstinence" from heterosexual intercourse or agree to use and complywith highly effective, uninterrupted contraception for 12 months after administration of UB-VV400 . Abstain from breastfeeding for 12 months following administration of UB-VV400. Men with partners of childbearing potential must commit to "true abstinence" from heterosexual intercourse or agree to use a highly effective form of contraception duringheterosexual contact with a pregnant individual or any individual of childbearing potential for 12 months after administration of UB-VV400, regardless of past vasectomy. Subjects must agree not to donate blood, organs, sperm/semen, and/or egg cells for use for at least 1 year following treatment with UB-VV400 alone or in combination with rapamycin. Insufficient data are available to define a duration of time sufficient to make a recommendation on when it is safe to donate any tissue; therefore, subjects should not donate any tissue after administration of UB-VV400.排除标准:Exclusion Criteria:
Women who are pregnant or breastfeeding. Subjects with current isolated central nervous system (CNS) tumor involvement. Subjects with a prior malignancy whose clinical course or management has the potential to interfere with the safety and/or efficacy evaluation of the clinical trial. Prior treatment with any of the following: allogeneic bone marrow transplantation, gene therapy, or adoptive cell transfer of any kind except for CAR T-cell therapy. Treatment with prior CD22-directed therapy except for UB-VV400. History of or active human immunodeficiency virus (HIV). Active hepatitis B (HepB) or hepatitis C (HepC). For subjects receiving rapamycin: a. History of angioedema; b. Pneumonitis (Grade 3 or greater). Ongoing Grade > 2 toxicities from the last line of anticancer therapy. Use of the following: Therapeutic systemic doses of corticosteroids (defined as > 20 mg prednisone equivalent) within 72 hours before dosing with UB-VV400. Approved targeted therapies: Allergies to rapamycin or supportive medications required for CAR T-cell toxicity management (eg, tocilizumab). Systemic autoimmune diseases or immunodeficiency diseases (except for well-controlled type I diabetes with hemoglobin A1C [HbA1c] less than 8% or well-controlled thyroid disease, as assessed by the treating physician). Ongoing CNS diseases (eg, seizure disorder, tremor, history of cerebral vascular accident [CVA]/recurrent transient ischemic attack [TIA]) that would preclude evaluation of immune effector cell-associated neurotoxicity syndrome (ICANS). Presence of uncontrolled angina or other acute uncontrolled heart disease. Myocardial infarction within the previous 6 months. New York Heart Association (NYHA) Class III or IV. History of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Actively receiving treatment in other interventional clinical trials. Note: continued follow-up on previous trials is allowed for survivorship, but no further investigational agents or assessments will be allowed.
引自 ClinicalTrials.gov, NCT06743503, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06743503,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。